ArticleFrontiers in cardiovascular medicine2026

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies.

Abhijnan Chattopadhyay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.